Robert Jan Lamers, MSc
Chief Executive Officer
Robert Jan has dedicated himself to the business development of innovations since the very start of his career. In 1995 after graduating in business economics at the University of Amsterdam, Robert Jan started in his first business development post, working for KPN Telecom introducing new telecommunication services and pricing schemes. In 1998 he became entrepreneur and was (co-)founder of several companies, including Maxwell Group and Investormatch. Since 2004 Robert Jan has been involved in innovation projects which focus on life sciences. After co-initiating the Life Sciences Fund Amsterdam, setting up the Life Science Center Amsterdam and revitalizing the Amsterdam Biomed Cluster, Robert Jan became the first director of the combined AMC UvA Technology Transfer Office, in 2008. In this role he was also the first co-director of the Life Sciences Center Amsterdam (2010) and later the director of AMC Ventures (2010).
Frank Baas, MD, Ph.D
Chief Scientific Officer
Frank Baas MD, PhD is a Professor of Neurogenetics, current head of the Neurogenetics laboratory at the AMC at the University of Amsterdam and a board certified Clinical Molecular geneticist. In 2006 he became Head of the Genome Analysis facility AMC. In 1991 he became assistant Professor at the Department of Neurology, University of Amsterdam Academic Medical Centre, and specializes in human molecular (neuro) genetics, staying on as an honorary staff member of the Netherlands Cancer Institute from 1991-1996. In 1989-1991 he was scientist at the Netherlands Cancer Institute, Division of Molecular Biology, establishing a research group on the regulation of gene expression and the identification of new mechanisms for multidrug resistance. Frank Baas obtained his MD (1982) and his PhD (1986) in Amsterdam (UvA). From 1987-1988 he was visiting scientist at the Massachusetts Institute of Technology, Cancer Center (D.E. Housman) and Harvard University (T. Maniatis).
Frank Baas has published over 250 peer-reviewed papers in the field of human genetics. He is also a named inventor on patents in the fields of neurodegeneration and cancer.
Marc van Dijk, Ph.D
Antibody program advisor
Marc van Dijk has over 17 years of industry experience in the antibody field and has held several senior management positions. He has a PhD in Molecular Biology and has worked as post-doctoral scientist at the University of California in San Diego. In 1997 he joined Medarex Europe as principle scientist. He subsequently joined Genmab at its inception in 1999 and held various management positions, including Vice President antibody technology. He was instrumental in setting-up the R&D team and was involved in the set up and management of partnerships with Immunex (now Amgen) and Roche. In June 2005 joined Innogenetics in Ghent, Belgium as Director of applied research and development, where he was responsible for the development of a new micro-array technology platform and overall product development for the diagnostic arm of Innogenetics in the fields of tissue typing, neurodegeneration and infectious disease. He is currently Chief Technology Officer of 4-Antibody AG, and guides the Regenesance antibody program.
He is inventor on several patents and author on publications in leading scientific journals including Cell, PNAS, J. Clin. Invest. and J. Exp. Med.